Side-by-side comparison of AI visibility scores, market position, and capabilities
Neurona Therapeutics develops interneuron cell therapies derived from human iPSCs to repair dysregulated neural circuits; lead program NRTX-1001 is in Phase 1/2 trials for drug-resistant focal epilepsy;
Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.